By Dean Seal
Shares of Vanda Pharmaceuticals jumped after Cycle Pharmaceuticals reaffirmed its proposal to buy the company for $8 a share.
The stock was up 18% at $5.22 in early trading. Shares have gained 24% since the start of the year.
Cycle said Monday morning that it is still offering to buy Vanda for $8 a share in cash despite Vanda's board refusing to engage with Cycle and rejecting its proposal on Oct. 7.
"Vanda's board and management team … have continued to prioritize their own interests and self-preservation with egregious actions that blatantly disenfranchise Vanda shareholders," Cycle said.
Vanda rejected proposals from both Cycle and the company Future Pak earlier this year, calling each inadequate. In June, Future Pak formally withdrew its offer to buy the company for $8.50 to $9 a share.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
October 14, 2024 10:28 ET (14:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.